8 active not recruiting. 8 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Active not recruiting 8 |
| Phase 2 | 5 | Active not recruiting 5 |
Follow Inflammation: new trials by email Literature Review of Inflammation trials Research Report on Inflammation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa) AZD7760, Placebo - Staphylococcus Aureus | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 242 | 2024-12-30 | 2026-10-28 |
| Comparison Between Carbapenems and Noncarbapenem Beta-lactam Antibiotics in Septic Burn Patients Meropenem I.V. 2g as a 3 hour infusion every 8 hours, Tazocin (pipercillin/tazobactam) - Sepsis | Phase 1 / Phase 2 | Active not recruiting | Ain Shams University | 400 | 2024-01-01 | 2025-10-03 |
| Omega-3 Fatty Acid Lipidomics in Diabetes Peripheral Neuropathy Fish Oil Concentrate, 1000 Mg Oral Capsule, Salsalate Oral Tablet - Diabetic Neuropathies | Phase 1 / Phase 2 | Active not recruiting | University of Iowa | 100 | 2023-06-12 | 2026-04-06 |
| Salt-Sensitivity and Immunity Cell Activation Furosemide 40 mg - High Blood Pressure, Salt; Excess | Phase 1 / Phase 2 | Active not recruiting | Vanderbilt University Medical Center | 20 | 2021-09-01 | 2025-10-21 |
| Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome tofacitinib, Placebo - Sjogren's Syndrome | Phase 1 / Phase 2 | Active not recruiting | National Institute of Dental and Craniofacial Research (NIDCR) | 23 | 2021-05-18 | 2025-12-18 |
| Imaging of Neuro-Inflammation and the Risk for Post-Traumatic Epilepsy [18F]DPA-714 Positron Emission Tomography Scan - Epilepsy, Post-Traumatic | Phase 1 | Active not recruiting | University of California, Davis | 30 | 2020-02-01 | 2026-09-14 |
| Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma iC9-CAR19 T cells, Bendamustine, Fludarabine - Lymphoma, Lymphoma, B-Cell | Phase 1 | Active not recruiting | UNC Lineberger Comprehensive Cancer Center | 12 | 2019-03-12 | 2026-07-31 |
| Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL iC9-CAR19 cells, Rimiducid, Cyclophosphamide - Acute Lymphoblastic Leukemia, Immune System Diseases | Phase 1 | Active not recruiting | UNC Lineberger Comprehensive Cancer Center | 15 | 2012-03-22 | 2026-06-10 |
Cytokine Release Syndrome (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Sepsis (2) · Brain Injuries, Traumatic (1) · Burns (1) · Diabetes Mellitus (1) · Diabetic Neuropathies (1) · Epilepsy, Post-Traumatic (1) · Hypertension (1) · Kidney Failure, Chronic (1) · Leukemia (1) · Lymphatic Diseases (1) · Lymphoma (1)
Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Systemic Inflammatory Response Syndrome (4) · Nervous System Diseases (3) · Hemic and Lymphatic Diseases (2) · Infections (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Shock (2) · Wounds and Injuries (2) · Arthritis (1) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1)
AP 1903 reagent (2) · Cyclophosphamide (2) · fludarabine (2) · fludarabine phosphate (2) · Bendamustine Hydrochloride (1) · Furosemide (1) · Meropenem (1) · Piperacillin (1) · Piperacillin, Tazobactam Drug Combination (1) · Tazobactam (1) · salicylsalicylic acid (1) · tofacitinib (1)
UNC Lineberger Comprehensive Cancer Center (2) · Ain Shams University (1) · AstraZeneca (1) · National Institute of Dental and Craniofacial Research (NIDCR) (1) · University of California, Davis (1) · University of Iowa (1) · Vanderbilt University Medical Center (1)
United States (7) · Egypt (1)
Annet Kirabo (1) · Aya A Bayoumy, MD (1) · Blake M Warner, D.D.S. (1) · Mark A Yorek, PhD (1) · Mohamed A Ali, MD (1) · Natalie Grover, MD (1) · Natalie S Grover, MD (1) · Osama R Abdelmalek, MD (1) · Rodica Pop-Busui, MD (1) · Thabet A Botros, MD (1)
K12CA120780 (1), R01DK126837 (1)